Bayer's Kogenate scores new FDA nod; Jerome Bettis and Sanofi want to know your 'AQ';

@FiercePharma: Lilly decries $450M award in Brazil as based on bad science, fuzzy math. Story | Follow @FiercePharma

@TracyStaton: Pfizer-AstraZeneca recap: Everything you need to know about today's drama, in bite-sized pieces. Report | Follow @TracyStaton

@EricPFierce: Canada orders Biolyse to halt production of injectable drug paclitaxel at a plant in Ontario. Story | Follow @EricPFierce

@CarlyHFierce: Chinese officials to shed some light on Glaxo probe at press briefing. More | Follow @CarlyHFierce

> The FDA has approved Bayer's Kogenate for routine prophylaxis in adults with hemophilia A. Release

> Pfizer ($PFE) is selling $4.5 billion of bonds to repay securities that mature within a year. Report

> Novartis ($NVS) has appointed Michael Willi as its group head of communications. More

> The FDA has accepted Teva's ($TEVA) supplemental New Drug Application for a pediatric indication for its QNASL nasal aerosol allergy treatment. Release

> India's Dr. Reddy's Laboratories posted a 25% rise in quarterly profit but missed analysts' expectations. Report

> L'Oreal's CEO says it's ready to cash in on its stake in Sanofi ($SNY) if it needs the money to put toward a larger takeover. More

> Mallinckrodt ($MNK) and Questcor ($QCOR) announced their early termination of the HSR Act Waiting Period, a condition for their proposed merger. Release

Medical Device News

@FierceMedDev: Elixir gets a CE mark for its latest bioresorbable stent. Article | Follow @FierceMedDev

@VarunSaxena2: FDA clears prescription video game for rehabilitation therapy. Story from yesterday | Follow @VarunSaxena2

@MichaelGFierce: 'Smart' Drug Delivery Could Aid Cancer Fight. More via Boston College Chronicle | Follow @MichaelGFierce

@EmilyWFierce: Ceterix Orthopaedics ropes in $18M to commercialize its arthroscopic surgical tools. News | Follow @EmilyWFierce

> Medtronic poaches GE exec to lead its $1.5B diabetes biz. Story

> GE Healthcare collaborates with CorTechs Labs on MRI scans. News

Biotech News

@FierceBiotech: AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline. Story | Follow @FierceBiotech

@JohnCFierce: This new company really explains why Boston is where it's at right now in biotech. Article | Follow @JohnCFierce

@DamianFierce: ICYMI: Shire pays $260M for Lumena, getting a rare liver disease treatment and a NASH drug. News | Follow @DamianFierce

@EmilyMFierce: Biochips, bioprinting offer alternative drug testing options. Special report | Follow @EmilyMFierce

> Marinus braves a cooling biotech IPO market with a $63M pitch. Story

> Pfizer's quest for AstraZeneca becomes political theater as MPs probe $106B offer. More

> GlaxoSmithKline's blockbuster dreams dashed as darapladib goes 0-for-2 in PhIII. Report

Biotech Research News

> Biochips, bioprinting offer alternative drug testing options. More

> Study: Heart attack stem cell treatment may offer little benefit. Article

> Naturally occurring molecule could treat Type 2 diabetes. News

> Harvard's heart disease-on-a-chip mimics real tissue and disease. Story

> FDA-approved genital warts drug could treat MERS. Article

> UCLA gets $4M for stem cell, digestive disease research. Item

Pharma Manufacturing News

> CSL opens $250M plant for hemophilia treatments. News

> Merck sells Colorado biologics plant to KBI. Report

> Lilly, Dobfar nailed with $450M fine, judge orders Brazilian plant closed. More

> WuXi says it intends to triple capacity at China plant. Article

> Canada regulators stop production at Biolyse Pharma in Ontario. Story

And Finally... Sanofi has signed on former NFL star Jerome Bettis to help it launch an anaphylaxis quiz during National Asthma and Allergy Awareness Month. Release

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.